Author Affiliations: Departments of Pediatrics and Neuro-oncology, MD Anderson Cancer Center (Dr Sadighi), and Department of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Medical School at Houston (Drs Butler and Koenig).
Objective To report new manifestations of cerebral folate deficiency, a rare metabolic autoimmune syndrome, in an adult.
Design Case report.
Setting University teaching hospital.
Patient A 58-year-old woman with progressive memory loss and myoclonus presented for medical attention. Results of cerebral spinal fluid analysis showed low levels of tetrahydrobiopterin and 5-methyltetrahydrofolate. The patient's serum folate level was normal. Serum contained folate receptor 1 blocking and binding antibodies.
Results The patient was treated successfully with folinic acid supplementation, and after 6 months of treatment, clinical symptoms had resolved.
Conclusions To our knowledge, we report the first case of adult-onset cerebral folate deficiency. Furthermore, this condition could represent a treatable form of early-onset dementia.
Typical autoimmune cerebral folate deficiency is characterized by normal early development followed by abrupt neurological regression. At approximately 4 months, affected children develop marked irritability, decelerated head growth, psychomotor retardation, ataxia, spasticity, dyskinesia (choreoathetosis and ballismus), visual loss, hearing loss, and myoclonic epilepsy.
A 58-year-old woman presented to the neurology clinic at The University of Texas at Houston, with progressive memory loss and myoclonus. The myoclonus consisted of brief jerks to the arms and legs that did not result in disability. She had a history of rheumatoid arthritis and migraine headaches. On physical examination, no neurological deficits other than mild myoclonus and impairment of short-term recall (formal neurocognitive testing was not performed) were noted. Results of cerebrospinal fluid (CSF) analysis showed low levels of tetrahydrobiopterin (8 nmol/L; reference, 10-30 nmol/L) and 5-methyltetrahydrofolate (29 nmol/L; reference, 40-120 nmol/L). The patient's serum folate level was normal (20.4 ng/mL; reference, >5.4 ng/mL [to convert to nanomoles per liter, multiply by 2.266]). Serum contained a folate receptor 1–blocking antibody titer of 0.41 pmol/mL (reference, <0.2 ML/mL) and an folate receptor 1–binding antibody titer of 0.81 ML IgG/mL (reference, <0.5 ML IgG/mL).
Our patient was treated successfully with folinic acid (25 mg/d), a stable form of metabolically active reduced folate that can access the CSF by the alternate folate carrier receptor.1 After 6 months of treatment, a second CSF 5-methyltetrahydrofolate level was 68 nmol/L (reference, 40-120 nmol/L), and clinical symptoms had resolved.
Folate is essential for the formation of biogenic amines and pterins in the central nervous system. Folate deficiency produces a variety of neurologic symptoms, including neuropsychiatric disturbances and movement disorders. In healthy adults, CSF folate levels do not decline with age,1 but CSF folate levels have been found to be lower in patients with late-onset Alzheimer disease than in age-matched control subjects.1
Folate is absorbed into the bloodstream via the gastrointestinal tract. In the bloodstream, folate binds to the folate receptor 1 on the basolateral endothelial surface of the choroid plexus. Through receptor-mediated endocytosis, folate is then transported across the blood-brain barrier into the CSF. Binding of the folate receptor 1 autoantibody to this receptor blocks the ability of the receptor to bind and transport folate.2
Classic autoimmune cerebral folate deficiency is characterized by normal early development followed by abrupt neurological regression. At approximately 4 months, children develop marked irritability, decelerated head growth, psychomotor retardation, ataxia, spasticity, dyskinesia (choreoathetosis and ballismus), visual loss, hearing loss, and myoclonic epilepsy.3,4 Treatment is with reduced folate in the form of folinic acid. Dose is titrated to maintain normal CSF 5-methyltetrahydrofolate levels. The optimal length of treatment is unknown.
A recent case report described a 15-year-old girl with cerebral folate deficiency and rheumatoid arthritis and no history of developmental abnormalities.5 The current case reported herein further defines the syndrome of autoimmune cerebral folate deficiency to include adult onset presenting with symptoms of dementia and myoclonus. This case highlights the importance for clinicians to consider CSF analysis, including 5-methyltetrahydrofolate levels, in all patients with a history of autoimmune disease and dementia.
Correspondence: Mary Kay Koenig, MD, Department of Pediatrics, Division of Child and Adolescent Neurology, University of Texas Medical School at Houston, 6431 Fannin St, MSB 3.151, Houston, TX 77030 (email@example.com).
Accepted for Publication: November 1, 2011.
Published Online: February 27, 2012. doi:10.1001/archneurol.2011.3036
Author Contributions:Study concept and design: Sadighi and Koenig. Acquisition of data: Sadighi. Analysis and interpretation of data: Sadighi and Butler. Drafting of the manuscript: Sadighi. Critical revision of the manuscript for important intellectual content: Sadighi, Butler, and Koenig. Study supervision: Sadighi, Butler, and Koenig.
Financial Disclosure: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.